Jiang Yimeng, Zhang Yan
Department of Cardiology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Feb;50(2):110-3. doi: 10.3760/cma.j.issn.0253-9624.2016.02.002.
Cardiovascular risk and related medical burden due to influenza in patients with chronic disease were higher than those of healthy subjects. As a result, influenza vaccination is recommended as a strategy for secondary prevention in cardiovascular disease by major cardiovascular organizations, but the prevalence of influenza vaccination in these population is still low. Whether influenza vaccine can prevent cardiovascular events such as myocardial infarction and death is still controversial based on current evidences from observational studies and case-control studies, which may result from study desion,subjects selection,outcome definition and sample size issues. Recent meta-analysis showed that influenza vaccination may reduce cardiovascular risk, but large-scale random controlled trials with adequately power should be conducted to confirm these findings as well as the target population for this strategy further.
慢性病患者因流感导致的心血管风险及相关医疗负担高于健康受试者。因此，主要心血管组织推荐将流感疫苗接种作为心血管疾病二级预防的一项策略，但这些人群中流感疫苗接种率仍较低。基于目前观察性研究和病例对照研究的证据，流感疫苗能否预防心肌梗死和死亡等心血管事件仍存在争议，这可能是由于研究设计、受试者选择、结局定义和样本量问题所致。近期的荟萃分析表明，流感疫苗接种可能降低心血管风险，但仍应开展具有足够效力的大规模随机对照试验，以进一步证实这些发现以及该策略的目标人群。
